Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies for cancer treatments, announced its upcoming participation in two major investor conferences. President and CEO Mark Velleca will present at the Stifel Healthcare Conference on November 19, 2024, at 4:10pm ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:00pm ET. Webcasts will be available on the company's website and archived for 90 days.

News Market Reaction – BDTX

+5.47%

+5.47% Session move

In the trading session that priced this news, BDTX gained 5.47%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

• Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024
• Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

FAQ

When is Black Diamond Therapeutics (BDTX) presenting at the Stifel Healthcare Conference in 2024?

Black Diamond Therapeutics will present at the Stifel Healthcare Conference on Tuesday, November 19, 2024, at 4:10pm ET.

When is BDTX's presentation at the Piper Sandler Healthcare Conference in 2024?

Black Diamond Therapeutics will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 3:00pm ET.

How long will BDTX's investor conference webcasts be available for viewing?

The webcasts will be archived and available for viewing on Black Diamond Therapeutics' website for 90 days after the presentations.

Where can I watch Black Diamond Therapeutics (BDTX) investor conference presentations?

The presentations can be viewed on Black Diamond Therapeutics' investor relations section of their website at www.blackdiamondtherapeutics.com.